157 related articles for article (PubMed ID: 9813027)
21. Structural analyses of human thymidylate synthase reveal a site that may control conformational switching between active and inactive states.
Chen D; Jansson A; Sim D; Larsson A; Nordlund P
J Biol Chem; 2017 Aug; 292(32):13449-13458. PubMed ID: 28634233
[TBL] [Abstract][Full Text] [Related]
22. Tolerance of 5-fluorodeoxyuridine resistant human thymidylate synthases to alterations in active site residues.
Landis DM; Gerlach JL; Adman ET; Loeb LA
Nucleic Acids Res; 1999 Sep; 27(18):3702-11. PubMed ID: 10471740
[TBL] [Abstract][Full Text] [Related]
23. Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors.
Kobayashi H; Takemura Y; Miyachi H; Skelton L; Jackman AL
Jpn J Cancer Res; 1995 Nov; 86(11):1014-8. PubMed ID: 8567390
[TBL] [Abstract][Full Text] [Related]
24. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
Sigmond J; Backus HH; Wouters D; Temmink OH; Jansen G; Peters GJ
Biochem Pharmacol; 2003 Aug; 66(3):431-8. PubMed ID: 12907242
[TBL] [Abstract][Full Text] [Related]
25. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
Jackman AL; Alison DL; Calvert AH; Harrap KR
Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
[TBL] [Abstract][Full Text] [Related]
26. Involvement of base excision repair in response to therapy targeted at thymidylate synthase.
Li L; Berger SH; Wyatt MD
Mol Cancer Ther; 2004 Jun; 3(6):747-53. PubMed ID: 15210861
[TBL] [Abstract][Full Text] [Related]
27. Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase.
Nivens MC; Felder T; Galloway AH; Pena MM; Pouliot JJ; Spencer HT
Cancer Chemother Pharmacol; 2004 Feb; 53(2):107-15. PubMed ID: 14605862
[TBL] [Abstract][Full Text] [Related]
28. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
Jackman AL; Melin CJ; Kimbell R; Brunton L; Aherne GW; Theti DS; Walton M
Biochim Biophys Acta; 2002 Jul; 1587(2-3):215-23. PubMed ID: 12084463
[TBL] [Abstract][Full Text] [Related]
29. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
Van Triest B; Pinedo HM; Giaccone G; Peters GJ
Ann Oncol; 2000 Apr; 11(4):385-91. PubMed ID: 10847455
[TBL] [Abstract][Full Text] [Related]
30. Properties of bacteriophage T4 thymidylate synthase following mutagenic changes in the active site and folate binding region.
LaPat-Polasko L; Maley GF; Maley F
Biochemistry; 1990 Oct; 29(41):9561-72. PubMed ID: 2271601
[TBL] [Abstract][Full Text] [Related]
31. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
[TBL] [Abstract][Full Text] [Related]
32. The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ in human leukaemia and colorectal carcinoma cell lines.
Estlin EJ; Balmanno K; Calvert AH; Hall AG; Lunec J; Newell DR; Pearson AD; Taylor GA
Br J Cancer; 1997; 76(12):1579-85. PubMed ID: 9413945
[TBL] [Abstract][Full Text] [Related]
33. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
van der Wilt CL; Kuiper CM; Peters GJ
Oncol Res; 1999; 11(8):383-91. PubMed ID: 10803742
[TBL] [Abstract][Full Text] [Related]
34. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs.
Theti DS; Jackman AL
Clin Cancer Res; 2004 Feb; 10(3):1080-9. PubMed ID: 14871988
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM
Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540
[TBL] [Abstract][Full Text] [Related]
36. Retroviral coexpression of thymidylate synthase and dihydrofolate reductase confers fluoropyrimidine and antifolate resistance.
Fantz CR; Shaw D; Moore JG; Spencer HT
Biochem Biophys Res Commun; 1998 Feb; 243(1):6-12. PubMed ID: 9473470
[TBL] [Abstract][Full Text] [Related]
37. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
38. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells.
Aherne GW; Hardcastle A; Raynaud F; Jackman AL
Biochem Pharmacol; 1996 May; 51(10):1293-301. PubMed ID: 8787544
[TBL] [Abstract][Full Text] [Related]
39. Antifolates in clinical development.
Takimoto CH
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-40-S18-51. PubMed ID: 9420020
[TBL] [Abstract][Full Text] [Related]
40. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
